New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag

• Published in: Kardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika Vol. 18; no. 6; pp. 80 - 87
• Main Authors: Ilyin, N. V., Ivanov, K. I., Martynyuk, T. V.
• Format: Journal Article
• Language: English
• Published: SILICEA-POLIGRAF» LLC 22-12-2019
• Subjects: combination therapy; pulmonary arterial hyperten¬sion; selexipag; specific therapy
• ISSN: 1728-8800; 2619-0125
• DOI: 10.15829/1728-8800-2019-6-80-87

Pulmonary arterial hypertension (PAH) is a rare chronic life-threatening disease. The treatment standards for PAH patients emphasize the need for early intervention and achievement of all treatment goals with the use of monotherapy or combinations. To date, strong evidence has been obtained that combination therapy with PAH-specific medications can significantly inhibit the development of the disease. Therefore, in modern guidelines, combination therapy is considered as a treatment standard for a significant proportion of patients with PAH. This publication presents a modern view of the selexipag practical using in early combination therapy in patients with PAH.